{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '1.2.4 Schedule of events Part 4: Table for PK sampling (Year 1)', 'Table 4 - PK Sampling schedule (Year 1)', 'PK sampling time', 'Day 1', 'Day 5', 'Day 14a,b', 'M1a', 'M2a', 'predose', 'End of', 'Infusion', 'Schedule', 'X', 'X', 'X', 'X', 'X', 'Sample ID', 'S1', 'S2', 'S3', 'S4', 'S5', 'a A window of 2 days for sample collection is permitted to ensure that sample collection does not fall on a weekend and allow for patient', 'flexibility.', 'b The sample will be drawn at local lab, if feasible per country regulation (no site visit).', 'Note: \"End\" refers to the end of the infusion period; these samples should be collected within 15 minutes prior to the end of the infusion from the', 'side of the body opposite the alemtuzumab infusion site.', '1.2.5 Schedule of events Part 5: Table for PK sampling (Year 2)', 'Table 5 - PK sampling schedule (Year 2)', 'PK sampling time', 'M12', 'M12', 'M12', 'M13a', 'M14a', 'Day 1', 'predose', 'Day 3 EOI', 'Day 12a,b', 'Schedule', 'X', 'X', 'X', 'X', 'X', 'Sample ID', 'S1', 'S2', 'S3', 'S4', 'S5', 'a A window of +2 days for sample collection is permitted to ensure that sample collection does not fall on a weekend.', 'b', 'The sample will be drawn at local lab, if feasible per country regulation (no site visit).', 'Note: \"EOI\" refers to the end of the infusion period; these samples should be collected within 15 minutes prior to the end of the infusion from the', 'side of the body opposite the alemtuzumab infusion site.', 'Property of the Sanofi Group - strictly confidential', 'Page 21', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '2', 'TABLE OF CONTENTS', 'AMENDED CLINICAL TRIAL PROTOCOL NO. 0505', '1', 'PROTOCOL AMENDMENT CHANGES TABLE', '2', '1', 'FLOW CHARTS', '13', '1.1', 'GRAPHICAL STUDY DESIGN', '13', '1.2', 'STUDY FLOW CHART', '14', '1.2.1', 'Schedule of events Part 1 (Year 1)', '14', '1.2.2', 'Schedule of events Part 2 (Year 2)', '17', '1.2.3', 'Schedule of events Part 3 (Safety monitoring phase Year 3 - Year 5)', '19', '1.2.4', 'Schedule of events Part 4: Table for PK sampling (Year 1)', '21', '1.2.5', 'Schedule of events Part 5: Table for PK sampling (Year 2)', '21', '2', 'TABLE OF CONTENTS', '22', '2.1', 'LIST OF TABLES', '28', '3', 'LIST OF ABBREVIATIONS', '29', '4', 'INTRODUCTION AND RATIONALE', '31', '5', 'STUDY OBJECTIVES', '37', '5.1', 'PRIMARY', '37', '5.2', 'SECONDARY', '37', '6', 'STUDY DESIGN', '38', '6.1', 'DESCRIPTION OF THE STUDY', '38', '6.2', 'DURATION OF STUDY PARTICIPATION', '39', '6.2.1', 'Duration of study participation for each patient', '39', '6.2.2', 'Determination of end of clinical trial (all patients)', '39', '6.3', 'INTERIM ANALYSIS', '39', '6.4', 'STUDY COMMITTEE', '40', '6.4.1', 'Scientific advisory committee:', '40', '6.4.2', 'Data monitoring committee', '40', '7', 'SELECTION OF PATIENTS', '41', 'Property of the Sanofi Group - strictly confidential', 'Page 22', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}